Peptides for Energy: What’s Actually Studied

No peptide is proven to boost energy in healthy, tired adults. The ones sold for energy — mainly MOTS-c, SS-31 and growth-hormone boosters like sermorelin — have been studied mostly in animals or in people with specific diseases, and the results are mixed. NAD+, the other big name, isn’t actually a peptide at all. Here’s what each one has really been tested for, what was found, and how it’s being sold.

What peptide gives you energy? The short, honest answer

If you’ve seen a med spa ad or heard a podcast promise that a peptide will fix your energy, here’s the plain facts: none of them has been shown to do that in people. A peptide is a short chain of amino acids, the same building blocks that make up proteins (our plain-language guide to peptides covers the basics). Several peptides are sold for energy, and a few have real science behind them. That science just isn’t about everyday tiredness.

Almost all the human “energy” data comes from people with rare inherited diseases, HIV or long COVID. Healthy adults who feel worn out haven’t been the subject of a trial with tiredness as the main thing measured, at least not one we could find. That doesn’t mean these compounds do nothing. It means nobody has shown what they do for you yet.

One more thing before we start: we don’t give doses, schedules or mixing instructions on this site. We don’t use a third party medical reviewer , and dosing advice isn’t something we’re willing to publish. Everything below is about what these compounds are, what the evidence shows, their legal status and how they’re sold.

What “energy” means in a study

Three very different things get called “energy,” and most marketing blurs them together. The first is feeling less tired, which researchers measure with questionnaires where people rate their own fatigue. The second is doing more, measured with exercise tests like how far you can walk in six minutes. The third is what happens inside your cells, measured in blood or tissue samples.

That third one matters most here. Many energy peptides are said to work on your mitochondria — the parts of your cells that turn food into usable energy. A compound can change what mitochondria do in a lab dish or a mouse without making a person feel any less tired. So when you read “boosts cellular energy,” ask which of the three kinds of energy was actually measured, and in whom.

At a glance: the energy peptides and what’s behind them

Here’s each compound, who it was actually tested in, and what came of it. Status links go to our Regulatory Tracker, which we update as the FDA changes things.

Peptides for mitochondria: MOTS-c and SS-31

MOTS-c

MOTS-c is a small peptide your own mitochondria make, and your body releases more of it when you exercise. In a 2021 study, researchers gave it to mice, and older mice ran about twice as long and twice as far on a treadmill as untreated mice (Reynolds et al., Nature Communications, 2021). The same study measured MOTS-c levels in 10 young men and found they rose sharply during exercise. It did not give MOTS-c to any of them.

That’s the gap. The evidence for MOTS-c as an energy booster is almost entirely animal studies so far — interesting, but nowhere near shown in humans. The human trials we’re aware of look at blood sugar and metabolism, not tiredness .

MOTS-c is not FDA-approved and isn’t on the list of substances pharmacies may compound, as of September 2026. FDA’s advisory panel on compounding (the PCAC, an outside group of experts that advises FDA) reviewed it in July 2026 for obesity and bone loss. Trade press reported a favorable vote, but that vote is non-binding, and FDA would still need to go through formal rulemaking before pharmacies could compound it (FDA PCAC meeting page).

SS-31 (elamipretide)

SS-31, also called elamipretide, has the most real human research of any compound on this list. It’s designed to attach to the inner walls of mitochondria and help them work better. It’s been tested in people with inherited mitochondrial diseases — rare conditions where the cell’s energy machinery doesn’t work properly from birth.

The biggest trial didn’t work out. MMPOWER-3 enrolled 218 adults with primary mitochondrial myopathy, an inherited disease that weakens muscles because their mitochondria are faulty. After six months, elamipretide did no better than a placebo (a look-alike shot with no drug in it) on either main goal: how far people could walk in six minutes, or how tired they felt (Karaa et al., Neurology, 2023). The drug was well tolerated over those six months.

The story in Barth syndrome is different. Barth syndrome is a rare inherited disease that weakens the heart and muscles. In a small trial of 12 people, elamipretide also missed its walking and fatigue goals over 12 weeks (Genetics in Medicine, 2021). But among the 8 people who kept taking it in the longer, open-label follow-up — where everyone knew they were getting the real drug — walking distance and fatigue scores both improved by about a quarter at 36 weeks. Longer-term follow-up out to 168 weeks has also been published (PubMed).

Elamipretide is FDA-approved only for Barth syndrome, a rare inherited disease, in patients weighing at least 30 kg (about 66 pounds), as of September 2026. It’s sold as Forzinity. The FDA granted accelerated approval, meaning approval based on an early sign of benefit — here, stronger knee-straightening muscles — that still has to be confirmed in a new trial (FDA; approval letter). That approval says nothing about everyday fatigue in healthy people.

Is NAD a peptide? What NAD+ actually is

No. NAD+ is a coenzyme — a helper molecule that enzymes (the proteins that run chemical reactions in your body) need to do their jobs. It’s not made of amino acids, so it isn’t a peptide, even though clinics and telehealth sites often sell it right alongside peptides. Your cells use it to turn food into energy.

Most human trials don’t use NAD+ itself. They use nicotinamide riboside (NR), a vitamin B3 pill your body converts into NAD+. In a 2018 trial of 30 healthy adults aged 55 to 79, NR raised NAD+ levels in blood cells by about 60% compared with placebo (Nature Communications, 2018). It didn’t change how much people could exercise.

The closest thing to a fatigue trial is in long COVID. In a 2025 randomized trial of 58 adults, NR roughly tripled NAD+ levels within weeks — but it did not improve fatigue, thinking, sleep or mood compared with placebo (eClinicalMedicine, 2025). The researchers saw some improvement within the group after 10 weeks, but that kind of before-and-after comparison can’t rule out the placebo effect, and they called for larger trials. Raising NAD+ levels, in other words, hasn’t yet translated into feeling less tired.

NAD+ injections and IV drips — the version most clinics sell — are a separate thing from NR pills, and they’re even less studied. NAD+ is not FDA-approved as a drug. It’s in FDA’s Category 1, meaning FDA doesn’t currently intend to act against licensed pharmacies that compound it while the agency evaluates it, as of September 2026. That’s a holding pattern, not FDA approval (FDA 503A bulk substances page).

Growth hormone boosters and “vitality” claims

Sermorelin, CJC-1295, ipamorelin and tesamorelin are growth hormone secretagogues — compounds that nudge your body to release more of its own growth hormone. They’re sold for “vitality,” better sleep and faster recovery. For a deeper look at this family, see our Growth Hormone Secretagogues & Muscle hub.

There is some human research, but in narrow groups. In a 12-month trial of 39 obese adults with low growth hormone, tesamorelin raised a growth-related hormone called IGF-1, and people whose IGF-1 rose more also had faster muscle recovery after exercise, as measured by a special kind of MRI scan (Journal of Clinical Endocrinology & Metabolism, 2014). That’s a link, not a clear cause, and it’s a cell-level measure — not how tired people felt. A 20-week trial of 152 older adults found improvements in some thinking skills, especially planning and organizing (Baker et al., 2012). We didn’t find any trial with tiredness as the main outcome in healthy adults.

Their legal status varies a lot, so here it is compound by compound:

• Tesamorelin is FDA-approved only for reducing belly fat in adults with HIV-related lipodystrophy, as of September 2026. Lipodystrophy here means a change in where the body stores fat, often adding fat deep in the belly. It’s sold as Egrifta, and its label says it isn’t for weight loss (FDA label). It is not approved for energy or fatigue.
• Sermorelin was once FDA-approved as Geref, mainly for growth hormone deficiency in children, but the maker stopped selling it in 2008. FDA found in 2013 that it wasn’t pulled for safety or effectiveness reasons (Federal Register). Whether pharmacies can currently compound it is still being confirmed.
• CJC-1295 is not FDA-approved and isn’t on the list of substances pharmacies may compound, as of September 2026.
• Ipamorelin is not FDA-approved and is on FDA’s Category 2 list — substances FDA says may pose significant safety risks when compounded, so FDA may act against pharmacies that use them — as of September 2026 (FDA Category 2 page).

Peptides for energy and focus

If you’ve searched “best peptide for energy and focus,” you’ve probably seen Semax. Semax is a claim about focus and the brain, not physical energy. The research is small and mostly published in Russian, so there’s very little an English-speaking reader or doctor can check. Our Cognitive & Focus hub goes deeper.

Semax is not FDA-approved and isn’t on the list of substances pharmacies may compound, as of September 2026. FDA’s advisory panel reviewed it in July 2026, and trade press reported a favorable non-binding vote. That vote doesn’t make it compounding-eligible.

Does BPC-157 increase energy?

No study has looked at BPC-157 and energy. Its research is about tissue repair — tendons, muscles and the gut — and it’s mostly been done in rats. When you see it in an “energy stack,” that’s marketing, not evidence. Our BPC-157 entry covers what’s actually known.

BPC-157 is not FDA-approved and isn’t on the list of substances pharmacies may compound, as of September 2026. FDA’s advisory panel reviewed it in July 2026, with a favorable non-binding vote reported in trade press. Formal rulemaking would still be required.

What peptides make you feel good? Mood, motivation and celebrity claims

No peptide has good human evidence for improving mood or motivation in healthy adults. The long-COVID NAD+ trial above looked at mood and found no difference from placebo. Most “feel good” claims come from personal stories, not trials.

You’ll also see celebrity names attached to peptides. We don’t report on what any specific person may or may not use. What a famous person takes tells you nothing about whether it works or is safe for you.

Where these are actually sold — and what that does and doesn’t mean

Energy peptides reach people through four main channels, and each one guarantees very different things. None of them means a product is safe or legal to use just because you can buy it. Here’s the honest picture.

A doctor’s prescription filled at a licensed pharmacy. This applies only to the two FDA-approved products: Forzinity, for Barth syndrome, and Egrifta, for HIV-related belly fat. You get a product made under FDA manufacturing oversight and a doctor accountable for how you use it — for those specific conditions. Neither is approved for energy.

Med spas and clinics. These dominate the search results for “peptides for energy.” They sell injections, nasal sprays and capsules and usually say the product comes from a compounding pharmacy — a pharmacy that mixes its own versions of drugs. A compounding pharmacy isn’t FDA-approved, and FDA doesn’t review compounded drugs for safety or effectiveness, but a licensed pharmacist is accountable for what’s made. Eligibility matters here: NAD+ sits in FDA’s Category 1 holding pattern, ipamorelin is on the Category 2 safety-risk list, and MOTS-c, CJC-1295 and Semax have no current pathway for compounding on FDA’s lists, as of September 2026.

Telehealth companies. These sell subscriptions after an online evaluation. A licensed prescriber is involved, which adds medical oversight, but the product is still compounded and carries the same limits as above.

“Research use only” websites. These sell MOTS-c, CJC-1295, ipamorelin, BPC-157 and others directly to anyone, labeled “not for human consumption.” There’s no prescription, no medical oversight and no FDA manufacturing oversight. There’s also no guarantee the vial contains what the label says, or in the amount it says. If you’re weighing providers, our reviews section compares vendors on testing and transparency.

For the latest status on every compound here, check the Regulatory Tracker.

If you’re tired all the time

Constant tiredness usually has a cause a doctor can test for — poor sleep, a thyroid problem, low iron and other common, fixable issues. It’s worth ruling those out before looking at anything experimental. A basic blood panel can answer more than any peptide study so far. For more on the wider longevity conversation, see our Longevity & Anti-Aging hub, and if weight is part of the picture, our Weight Loss & GLP-1 hub.

FAQs about peptides for energy